» Articles » PMID: 29291252

TFPIα Interacts with FVa and FXa to Inhibit Prothrombinase During the Initiation of Coagulation

Overview
Journal Blood Adv
Specialty Hematology
Date 2018 Jan 2
PMID 29291252
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue factor pathway inhibitor α (TFPIα) inhibits prothrombinase, the thrombin-generating complex of factor Xa (FXa) and factor Va (FVa), during the initiation of coagulation. This inhibition requires binding of a conserved basic region within TFPIα to a conserved acidic region in FXa-activated and platelet-released FVa. In this study, the contribution of interactions between TFPIα and the FXa active site and FVa heavy chain to prothrombinase inhibition were examined to further define the inhibitory biochemistry. Removal of FXa active site binding by mutation or by deletion of the second Kunitz domain (K2) of TFPIα produced 17- or 34-fold weaker prothrombinase inhibition, respectively, establishing that K2 binding to the FXa active site is required for efficient inhibition. Substitution of the TFPIα basic region uncharged residues (Leu252, Ile253, Thr255) with Ala (TFPI-AAKA) produced 5.8-fold decreased inhibition. This finding was confirmed using a basic region peptide (Leu252-Lys261) and Ala substitution peptides, which established that the uncharged residues are required for prothrombinase inhibitory activity but not for binding the FVa acidic region. This suggests that the uncharged residues mediate a secondary interaction with FVa subsequent to acidic region binding. This secondary interaction seems to be with the FVa heavy chain, because the FV Leiden mutation weakened prothrombinase inhibition by TFPIα but did not alter TFPI-AAKA inhibitory activity. Thus, efficient inhibition of prothrombinase by TFPIα requires at least 3 intermolecular interactions: (1) the TFPIα basic region binds the FVa acidic region, (2) K2 binds the FXa active site, and (3) Leu252-Thr255 binds the FVa heavy chain.

Citing Articles

Mathematical modeling identifies clotting factor combinations that modify thrombin generation in normal and factor VIII-, IX-, or XI-deficient blood.

Stobb M, Neeves K, Monroe D, Sindi S, Leiderman K, Fogelson A Res Pract Thromb Haemost. 2024; 8(7):102570.

PMID: 39434958 PMC: 11491717. DOI: 10.1016/j.rpth.2024.102570.


Factor V variants in bleeding and thrombosis.

Mohapatra A, Todaro A, Castoldi E Res Pract Thromb Haemost. 2024; 8(1):102330.

PMID: 38404937 PMC: 10883835. DOI: 10.1016/j.rpth.2024.102330.


Post-transcriptional control of haemostatic genes: mechanisms and emerging therapeutic concepts in thrombo-inflammatory disorders.

Danckwardt S, Tregouet D, Castoldi E Cardiovasc Res. 2023; 119(8):1624-1640.

PMID: 36943786 PMC: 10325701. DOI: 10.1093/cvr/cvad046.


Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

Reitsma S, Holle L, Bouck E, Monroe D, Mast A, Burthem J J Thromb Haemost. 2023; 21(3):467-479.

PMID: 36696199 PMC: 10111213. DOI: 10.1016/j.jtha.2022.10.005.


Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI.

Miyazawa K, Fogelson A, Leiderman K Biophys J. 2022; 122(1):99-113.

PMID: 36403087 PMC: 9822800. DOI: 10.1016/j.bpj.2022.11.023.


References
1.
Santamaria S, Reglinska-Matveyev N, Gierula M, Camire R, Crawley J, Lane D . Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem. 2017; 292(22):9335-9344. PMC: 5454113. DOI: 10.1074/jbc.M116.769570. View

2.
Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

3.
Pomowski A, Ustok F, Huntington J . Homology model of human prothrombinase based on the crystal structure of Pseutarin C. Biol Chem. 2014; 395(10):1233-41. DOI: 10.1515/hsz-2014-0165. View

4.
Zoller B, Dahlback B . Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994; 343(8912):1536-8. DOI: 10.1016/s0140-6736(94)92940-8. View

5.
Monkovic D, Tracy P . Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem. 1990; 265(28):17132-40. View